国际皮肤性病学杂志    2006 32 (6): 380-382   ISSN: 2096-5540  CN: 32-1880/R   白介素-10与银屑病 权晟, 杨森, 张学军 安徽医科大学皮肤病研究所、第一附属医院皮肤科, 合肥230022 收稿日期 2006-01-26  修回日期 null  网络版发布日期 null 参考文献  [1] Fiorentino DF,Bond MW,Mosmann TR.Two types of mouse T helper cell.IV.Th2 clones secrete a factor that inhibits cytokine production by Thl clones.J Exp Med,1989,170:2081-2095. [2] Fickenscher H,Hor S,Kupers H,et al.The interleukin-10 family of cytokines.Trends Immunol,2002,23:89-96. [3] Weiss E,Mamelak AJ,La Morgia S,et al.The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases.J Am Acad Dermatol,2004,50:657-675; quiz 676-678. [4] Asadullah K,Sterry W,Stephanek K,et al.IL-10 is a key cytokine in psoriasis.Proof of principle by IL-10 therapy:a new therapeutic approach.J Clin Invest,1998,101:783-794. [5] Jacob SE,Nassiri M,Kerdel FA,et al.Simultaneous measurement of multiple Thl and Th2 serum cytokines in psoriasis and correlation with disease severity.Mediators Inflamm,2003,12:309-313. [6] Kingo K,Ratsep R,Koks S,et al.Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility.J Dermatol Sci,2005,37:111-113. [7] Asadullah K,Eskdale J,Wiese A,et al.Interleukin-10 promoter polymorphism in psoriasis.J Invest Dermatol,2001,116:975-978. [8] Hensen P,Asadullah K,Windemuth C,et al.Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis.Br J Dermatol,2003,149:381-385. [9] Kingo K,Koks S,Silm H,et al.IL-10 promoter polymorphisms influence disease severity and course in psoriasis.Genes Immun,2003,4:455-457. [10] Asadullah K,Friedrich M,Hanneken S,et al.Effects of systemic interleukin-10 therapy on psoriatic skin lesions:histologic,immunohistologic,and molecular biology findings.J Invest Dermatol,2001,116:721-727. [11] Reich K,Garbe C,Blaschke V,et al.Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation,downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.J Invest Dermatol,2001,116:319-329. [12] McInnes IB,Illei GG,Danning CL,et al.IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis.J Immunol,2001,167:4075-4082. [13] Seifert M,Sterry W,Effenberger E,et al.The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes.Arch Dermatol Res,2000,292:164-172. [14] Seifert M,Gruenberg BH,Sabat R,et al.Keratinocyte unresponsiveness towards interleukin-10:lack of specific binding due to deficient IL-10 receptor 1 expression.Exp Dermatol,2003,12:137-144. [15] Asadullah K,Docke WD,Ebeling M,et al.Interleukin 10 treatment of psoriasis:clinical results of a phase 2 trial.Arch Dermatol,1999,135:187-192. [16] Friedrich M,Docke WD,Klein A,et al.Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis.J Invest Dermatol,2002,118:672-677. [17] Kimball AB,Kawamura T,Tejura K,et al.Clinical and immunologic assessment of patients with psoriasis in a randomized,double-blind,placebo-controlled trial using recombinant human interleukin 10.Arch Dermatol,2002,138:1341-1346. 通讯作者: 张学军,email:ayzxj@vip.sina.com